Atlas Trials

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Clinical trial NCT05535959 · COMPLETED

Trial details

NCT number
NCT05535959
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2022-09-15
Primary completion
2022-11-09
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.